

Biologics in General Medicine

Bearbeitet von
W.-H Boehncke, H.H Radeke

1. Auflage 2007. Buch. xviii, 190 S. Hardcover

ISBN 978 3 540 29017 9

Format (B x L): 19,3 x 24,2 cm

Gewicht: 621 g

[Weitere Fachgebiete > Medizin > Klinische und Innere Medizin > Immunologie](#)

Zu [Leseprobe](#)

schnell und portofrei erhältlich bei


DIE FACHBUCHHANDLUNG

Die Online-Fachbuchhandlung [beck-shop.de](#) ist spezialisiert auf Fachbücher, insbesondere Recht, Steuern und Wirtschaft. Im Sortiment finden Sie alle Medien (Bücher, Zeitschriften, CDs, eBooks, etc.) aller Verlage. Ergänzt wird das Programm durch Services wie Neuerscheinungsdienst oder Zusammenstellungen von Büchern zu Sonderpreisen. Der Shop führt mehr als 8 Millionen Produkte.

W.-H. Boehncke · H.H. Radeke (Eds.) *Biologics in General Medicine*

W.-H. Boehncke · H.H. Radeke (Eds.)

Biologics in General Medicine

With 51 Figures in 95 Parts and 23 Tables

 Springer

PROF. DR. MED. WOLF-HENNING BOEHNCKE MA
Department of Dermatology
Clinic of the Johann-Wolfgang-Goethe-University
Theodor-Stern-Kai 7
60590 Frankfurt

PROF. DR. MED. HEINFRIED H. RADEKE
Dr.-Hans-Schleussner-Foundation Immune Pharmacology
pharmazentrum frankfurt, Bldg. 75, Room 103
Johann-Wolfgang-Goethe-University
Theodor-Stern-Kai 7
60590 Frankfurt

ISBN 978-3-540-29017-9 Springer-Verlag Berlin Heidelberg New York

Library of Congress Control Number: 2006938888

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

Springer is a part of Springer Science+Business Media
<http://www.springer.com>

© Springer-Verlag Berlin Heidelberg 2007

Printed in Germany

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about the application of operative techniques and medications contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Editor: Dr. Ute Heilmann
Desk Editor: Dörthe Mennecke-Bühler
Copy-editing: WS Editorial Ltd, Shrewsbury, UK
Production Editor: Joachim W. Schmidt

Cover design: eStudio Calamar, Spain

Typesetting: FotoSatz Pfeifer GmbH, D-82166 Gräfelfing
Printed on acid-free paper – 21/3150 – 5 4 3 2 1 0

Preface

The idea for this book was born during the symposium on biologics organized by ZAFES (Center for Drug Research, Development and Safety at the University of Frankfurt am Main) in September 2005. Highly distinguished researchers specializing in the field of biologics had gathered together to exchange information on this relatively new subject. Realizing that this symposium was one of the few sources of condensed information on biologics, it became obvious that we had to create a means of informing an interested wider circle of scientists and especially general clinicians.

Therefore, the editors of this book suggested to the researchers at the symposium and also to prominent scientists and clinicians involved in the development and application of biologics as their major field of interest the idea of assembling this compendium. We received an overwhelmingly positive response – thankfully also from the publisher – most being more than willing to support this innovative project with highly relevant chapters on the latest state of the art. As we were eager to fill the information gap with up-to-date knowledge, the project had to be finished within the shortest time possible. To all experienced with editing this was obviously a challenge and we are very thankful to all the contributors that our timeline had to be extended by only a few months. This book represents a collection of the most recent knowledge on biologics written by people who have been active in the field for many years.

*Wolf-Henning Boehncke
Heinfried H. Radeke*

Contents

1	Introduction: Definition and Classification of Biologics	
	W.-H. BOEHNCKE, H.H. RADEKE	1
1.1	Aims	1
1.2	Perspectives	2
I	Development and Pre-clinical Pharmacology of Biologics	
2	Infliximab: From the Idea to the Product	
	M. WIEKOWSKI, CH.E. ANTONI	5
2.1	Characteristics and Biological Activity	5
2.1.1	Antibody Characteristics	5
2.1.2	Other Mechanisms of Infliximab Activity	5
2.2	Administration	6
2.3	Therapeutic Indications	6
2.4	Pharmacokinetics	7
2.4.1	Pharmacokinetics in Rheumatoid Arthritis Patients	7
2.4.2	Pharmacokinetics in Crohn's Disease	9
2.4.3	Pharmacokinetics in Psoriasis	9
2.4.4	Pharmacokinetics in Pediatric Crohn's Patients	9
2.5	Relationship Between Infliximab Concentration and Clinical Response ...	10
2.6	Antibody Formation Against Infliximab	10
2.6.1	HACA Formation and Clinical Response	11
2.7	Infusion Reactions/Delayed Hypersensitivity Reactions	11
2.8	Alternative Routes of Administration	11
2.9	Summary	12
	References	12
3	Adalimumab	
	J. SALFELD, H. KUPPER	14
3.1	Pharmacology	15
3.1.1	Mode of Action	15
3.1.2	Pharmacodynamics	16
3.1.3	Pharmacokinetics	16
3.1.4	Adalimumab Comparisons with Infliximab and Etanercept	16
3.2	Indications	18
3.3	Pivotal Studies in Rheumatoid Arthritis	18
3.3.1	Adalimumab Plus Methotrexate	19

3.3.2	Monotherapy	19
3.3.3	Adalimumab Plus Traditional DMARDs	22
3.3.4	Early Rheumatoid Arthritis	22
3.4	Pivotal Studies in Psoriatic Arthritis	23
3.5	Pivotal Study in Ankylosing Spondylitis	25
3.6	Future Indications	25
3.6.1	Psoriasis	25
3.6.2	Crohn's Disease	25
3.7	Safety	26
3.8	Summary	27
	References	28
4	Etanercept	
	CH.T. MOLTA	32
4.1	Structure	32
4.2	Pharmacokinetics	32
4.2.1	Absorption	32
4.2.2	Distribution	34
4.2.3	Metabolism and Elimination	34
4.2.4	Age	34
4.2.5	Gender	34
4.2.6	Patients with Renal or Hepatic Insufficiency	34
4.2.7	Drug Interactions	35
4.3	Pharmacodynamics	35
4.3.1	Mode of Action	35
4.3.2	Pharmacodynamics in Disease States	36
4.4	Indications	38
4.5	Summary	40
	Key References	40
	References	40
5	Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development	
	S. JAHN, K. SCHMITT-RAU	42
5.1	Introduction	42
5.2	Development and Characterization of the Antibody	43
5.3	Efalizumab: From Mode of Action to the Treatment of Psoriasis	44
5.3.1	Psoriasis: Prevalence, Characteristics and Therapeutic Options	44
5.3.2	Pathogenesis of Psoriasis: Targets for Efalizumab	45
5.3.3	Efalizumab: Mechanism of Action	46
5.4	Pharmacology and Toxicology of Efalizumab	47
5.4.1	Preclinical Studies	47
5.4.2	Pharmacodynamics	47
5.4.3	Pharmacokinetics	48
5.5	Indication(s)	49
5.6	Summary	49
	References	49

6	Monoclonal Antibody Targeted Radiation Cancer Therapy	
	L.M.M. KELLER, C.A. BOSWELL, D.E. MILENIC, ERIK D. BRADY, MARTIN W. BRECHBIEL	50
6.1	Overview	50
6.2	Introduction and Background	50
6.3	The Radioisotope	51
6.4	Linking the Radionuclide to Protein	54
6.5	The Protein Vehicle	56
6.6	Conclusions	57
	References	57
7	The Production of Biopharmaceuticals	
	B. HUGHES, L.E. HANN	59
7.1	Introduction	59
7.2	The Success of Modern Biotechnology	60
7.3	The Science and Technology Behind Modern Biopharmaceuticals	61
7.4	Process Development	62
7.5	Biopharmaceutical Manufacturing	63
7.6	Quality Assurance and Quality Control	64
7.7	Facility Considerations	64
7.8	Biosimilar Products (or Follow-on Biologics)	65
7.9	Conclusion	65
	Key References	65
	Full Reference List	66
II	Disease-Specific Applications and Clinical Trials	
8	Treating Autoimmune Bullous Skin Disorders with Biologics	
	R. EMING, A. NIEDERMEIER, M. PFÜTZE, A. JACOBI, M. HERTL	69
8.1	Introduction	69
8.1.1	Autoimmune Bullous Skin Disorders	69
8.1.2	Immune Pathogenesis of Bullous Autoimmune Disorders	71
8.2	Rituximab (Anti-CD20 Monoclonal Antibody) in the Treatment of Autoimmune Bullous Skin Disorders	72
8.2.1	Biological Activity of Rituximab	72
8.2.2	Clinical Experience with Rituximab Therapy	73
8.2.3	Rituximab in Pemphigus	73
8.2.4	Rituximab in Epidermolysis Bullosa Acquisita	74
8.2.5	Toxicity of Rituximab Treatment and Adverse Effects	76
8.2.6	Contraindications for Treatment with Rituximab	76
8.3	Inhibitors of TNF- α in the Treatment of Autoimmune Bullous Skin Disorders	76
8.3.1	Central Role of TNF- α in Inflammation	76
8.3.2	Inhibition of TNF- α by Biologics	77
8.3.3	Inhibition of TNF- α in Pemphigus Vulgaris	78
8.3.4	Inhibition of TNF- α in Bullous Pemphigoid	79
8.4	Summary	79
	References	80

9	Biologics in Psoriasis	
	W.A. MYERS, W.-H. BOEHNCKE, A.B. GOTTLIEB	81
9.1	Introduction	81
9.1.1	Psoriasis	81
9.1.2	Mechanism of Disease	85
9.2	Etanercept	86
9.2.1	Structure and Mode of Action	86
9.2.2	Pharmacokinetics and Pharmacodynamics	86
9.2.3	Efficacy	87
9.2.4	Safety	88
9.2.5	Off-Label Use	89
9.3	Efalizumab	89
9.3.1	Structure and Mode of Action	89
9.3.2	Pharmacokinetics and Pharmacodynamics	89
9.3.3	Efficacy	90
9.3.4	Safety	91
9.3.5	Off-Label Use	92
9.4	Alefacept	92
9.4.1	Structure and Mode of Action	92
9.4.2	Pharmacokinetics and Pharmacodynamics	93
9.4.3	Efficacy	93
9.4.4	Safety	94
9.4.5	Off-Label Use	95
9.5	Infliximab	95
9.6	Adalimumab	95
	References	96
10	Biologic Agents in Psoriatic Arthritis	
	PH. MEASE	97
10.1	Introduction	97
10.2	Classification and Epidemiology	97
10.3	Genetic Epidemiology	97
10.4	Immunopathology	98
10.5	Clinical Features	98
10.6	Outcome Measures	101
10.7	Treatment	101
10.8	Biologic Agents	102
10.8.1	Etanercept	102
10.8.2	Infliximab	103
10.8.3	Adalimumab	104
10.9	Other Biologic Agents	105
10.9.1	Alefacept	105
10.9.2	Efalizumab	106
10.9.3	Abatacept	106
10.10	Other Potential Treatments	106
10.11	Cost-Effectiveness Analysis	107
10.12	Conclusion	107
	References	108

11	Biologic Therapies for Rheumatoid Arthritis Targeting TNF-α and IL-1	
	P.C. TAYLOR	111
11.1	Introduction	111
11.2	Biologic Therapies Targeting TNF- α	111
11.2.1	Rationale for TNF Blockade in the Treatment of Rheumatoid Arthritis	111
11.2.2	Clinical Studies of Anti-TNF Therapy	112
11.2.3	Safety of Biologic TNF Inhibitors	114
11.2.4	Infectious Complications	114
11.2.5	Congestive Cardiac Failure	115
11.2.6	Solid Tumours and Lymphoma	116
11.2.7	Other Toxicity Issues	116
11.2.8	Injection Site Reactions or Infusion-Related Reactions	117
11.2.9	Mechanism of Action of TNF Blockade	117
11.3	Targeting IL-1	118
11.4	Combination Anti-cytokine Therapies	119
11.5	Conclusions	120
	References	120
12	Biologics in Crohn's Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonists	
	J. SALFELD, P. RUTGEERTS	124
12.1	Clinical Features of Crohn's Disease	124
12.2	Pathogenesis of Crohn's Disease	124
12.3	Biologics for Use in Crohn's Disease	126
12.3.1	TNF Antagonists	130
12.3.2	Selective Adhesion Molecule Inhibitors	134
12.3.3	Anti-IL-12/IL-23 Antibodies	135
12.3.4	Anti-IFN- γ Antibodies	136
12.3.5	Anti-IL-6 Receptor Monoclonal Antibody	136
12.3.6	Miscellaneous	137
12.4	Biologics in Ulcerative Colitis	137
12.5	Summary and Outlook	137
	References	138
13	Multiple Sclerosis: New Immunobiologics	
	R. GOLD, R. HOHLFELD	141
13.1	Introduction	141
13.2	Immunopathogenesis of Multiple Sclerosis	141
13.3	Prominent Failure of TNF- α Targeting	142
13.4	Adverse Reactions in Highly Efficacious Anti- α 4-Integrin Therapy with Natalizumab	143
13.5	Currently Investigated Monoclonal Antibodies	144
13.5.1	Anti-CD52	144
13.5.2	Anti-CD25	144
13.5.3	Anti-CD20	145
13.5.4	Other Therapeutic Monoclonal Antibodies	145
13.6	Conclusions and Outlook	145
	References	146

14	Biologics in Cutaneous Lymphoma	
	M. BEYER, CH. ASSAF, W. STERRY	147
14.1	Introduction	147
14.2	Cutaneous T-Cell Lymphomas	148
14.2.1	Cutaneous B-Cell Lymphoma	149
14.3	Biologics in the Treatment of CTCL	149
14.3.1	DAB389-Interleukin-2 (DAB389IL-2)	149
14.3.2	Alemtuzumab	150
14.3.3	Rituximab	150
14.3.4	90Y-Ibritumomab Tiuxetan	151
14.3.5	Histone Deacetylase Inhibitors	152
	References	152
15	Biologics in Targeted Cancer Therapy	
	D. SCHRAMA, J.C. BECKER	153
15.1	Introduction	153
15.2	Chemoimmunoconjugates	154
15.3	Immunotoxins	156
15.4	Antibody-Cytokine Fusion Proteins	157
15.5	Evolving Approaches	160
15.6	Conclusions	162
	References	163
III	Safety and Perspectives	
16	Safety Aspects of Biologics: Lessons Learnt from Monoclonal Antibodies	
	CH.K. SCHNEIDER, J. LÖWER	169
16.1	Introduction	169
16.2	Intervention with Pleiotropic Cytokine Pathways	170
16.3	Intervention with Adhesion Molecules	171
16.4	Intervention with Growth Factor Receptors	172
16.5	Conclusion	173
	References	173
17	New Biological Therapeutics in the Genome Age	
	T.N.C. WELLS, S. SCHNIEPER-SAMEC	175
17.1	Introduction	175
17.2	Early Biotechnology Production of Human Cytokines and Hormones ..	176
17.3	Finding New Cytokine Orphans in the Human Genome: Early Excitement from Expressed Sequence Tags	177
17.4	Assembling the Complete Protein Collection: The Serono Secretome ..	177
17.5	Moving from the Protein to the Biological Activity: The Post-Genome Era	178
17.6	Strategies for Blocking Responses	180
17.6.1	Monoclonal Antibodies	180
17.6.2	Receptor Fusion Proteins	180
17.6.3	Protein Antagonists	180
17.6.4	Small Molecules: The Convenience of an Oral Medicine	180
17.7	Future Directions	180
	References	181

18 Evidence Based Medicine's Perspective on Biologics	
B. RZANY, A. NAST	184
18.1 What is EBM?	184
18.2 EBM Steps to Treating an Individual Patient	184
18.3 German S3 Guideline for the Treatment of Plaque Psoriasis	185
18.4 EBM and Biologics	185
18.5 Where Do Biologics Stand Among Other Systemic Treatments of Psoriasis?	186
References	186
Subject Index	187

List of Contributors

Christian E. Antoni, MD

Department of Clinical Immunology, Schering-Plough Research Institute
2015 Galloping Hill Road, Kenilworth, NJ 07033, USA

Chalid Assaf, MD

Cutaneous Lymphoma Section, Department of Dermatology and Allergy,
Skin Cancer Center Charité, Charité-Universitätsmedizin Berlin
Fabeckstr. 60–62, 14195 Berlin, Germany

Jürgen C. Becker, Prof. Dr. med., PhD

Department of Dermatology, University of Würzburg
Josef-Schneider Str. 2, 97080 Würzburg, Germany

Marc Beyer, Dr.

Department of Dermatology and Allergy, Skin Cancer Center Charité, Charité-
Universitätsmedizin Berlin, Fabeckstr. 60–62, 14195 Berlin, Germany

Wolf-Henning Boehncke, Prof. Dr. med., MA

Department of Dermatology, Johann-Wolfgang-Goethe-University
Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

C. Andrew Boswell, PhD

Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch,
National Cancer Institute, National Institutes of Health
10 Center Drive, Bethesda, MD 20892, USA

Erik D. Brady, PhD

Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch,
National Cancer Institute, National Institutes of Health
10 Center Drive, Bethesda, MD 20892, USA

Martin W. Brechbiel, PhD

Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch,
National Cancer Institute, National Institutes of Health
10 Center Drive, Building 10, Room 1B40, Bethesda, MD 20892-1088, USA

Rick Davis, MS, RPh

Complete Healthcare Communications, Inc., One Dickinson Drive
Chadds Ford PA 19317, USA

Rüdiger Eming, MD

Department of Dermatology and Allergology, University Hospital,
Philipps-University of Marburg, Deutschhausstraße 9, 35033 Marburg, Germany

Ralf Gold, MD

Experimentelle und Klinische Neuroimmunologie, Institut für MS-Forschung,
Bereich Humanmedizin der Universität Göttingen und Gemeinnützige
Hertie-Stiftung, Waldweg 33, 37073 Göttingen, Germany

Alice B. Gottlieb, MD, PhD

Department of Dermatology, Tufts-New England Medical Center
750 Washington Street, Boston, MA 02111, USA

Louane E. Hann, PhD

Wyeth BioPharma, One Burt Road, Andover, MA 01810, USA

Michael Hertl, MD

Department of Dermatology and Allergology, Philipps University
Deutschhausstraße 9, 35033 Marburg, Germany

Reinhard Hohlfeld, Prof.

Institute for Clinical Neuroimmunology, Klinikum Großhadern
Ludwig Maximilians University, Marchioninistraße 15, 81366 Munich, Germany

Brendan Hughes, PhD

The Wyeth BioPharma Campus at Grange Castle, Grange Castle International
Business Park, Clondalkin, Dublin 22, Ireland

Arnd Jacobi, MD

Department of Dermatology and Allergology, Philipps University
Deutschhausstraße 9, 35033 Marburg, Germany

Sigbert Jahn, MD, PhD

Serono GmbH, Freisinger Str. 5, 85716 Unterschleißheim, Germany

Lanea M.M. Keller, MS

Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch,
National Cancer Institute, National Institutes of Health
10 Center Drive, Bethesda, MD 20892, USA

Hartmut Kupper, Dr.

Abbott GmbH & Co., Knollstraße 50, 67061 Ludwigshafen, Germany

Johannes Löwer, Prof. Dr. med.

Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe (Federal Agency for Sera
and Vaccines), Paul-Ehrlich-Straße 51 – 59, 63225 Langen, Germany

Philip J. Mease, MD

Division of Rheumatology Research, Swedish Medical Center; University of
Washington School of Medicine, Seattle, WA, USA; Seattle Rheumatology
Associates, 1101 Madison St., Suite 1000, Seattle, WA 98104, USA

Diane E. Milenic, MS

Radioimmune & Inorganic Chemistry Section, Radiation Oncology Branch,
National Cancer Institute, National Institutes of Health
10 Center Drive, Bethesda, MD 20892, USA

Charles T. Molta, MD

Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA

Wendy A. Myers, MD

UMDNJ-Robert Wood Johnson Medical School, Psoriasis Center of Excellence
One Robert Wood Johnson Place, PO Box 19, New Brunswick, NJ 08903-0019, USA

Alexander Nast, Dr. med.

Division of Evidence-Based Medicine (dEBM), Klinik für Dermatologie,
Charité-Universitätsmedizin Berlin, Campus Charité Mitte
Schumannstr. 20/21, 10117 Berlin, Germany

Andrea Niedermeier, MD

Department of Dermatology and Allergology, Philipps University
Deutschhausstraße 9, 35033 Marburg, Germany

Martin Pfütz, MD

Department of Dermatology and Allergology, Philipps University
Deutschhausstraße 9, 35033 Marburg, Germany

Heinfried H. Radeke, Prof. Dr. med.

Dr.-Hans-Schleussner-Foundation Immune Pharmacology, pharmazentrum
frankfurt, Bldg. 75, Room 103, Johann-Wolfgang-Goethe-University
Theodor-Stern-Kai 7, 60590 Frankfurt, Germany

Berthold Rzany, Prof. Dr. med., ScM

Division of Evidence-Based Medicine (dEBM), Klinik für Dermatologie,
Charité-Universitätsmedizin Berlin, Campus Charité Mitte
Schumannstr. 20/21, 10117 Berlin, Germany

Paul Rutgeerts, Prof.

University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium

Jochen Salfeld, Dr.

Abbott Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA

Karlheinz Schmitt-Rau, PhD

Serono GmbH, Freisinger Str. 5, 85716 Unterschleissheim, Germany

Christian Schneider, Dr.

Mono- and Polyclonal Antibodies Section, Paul-Ehrlich-Institut, Bundesamt
für Sera und Impfstoffe (Federal Agency for Sera and Vaccines)
Paul-Ehrlich-Straße 51 – 59, 63225 Langen, Germany

Sonia Schnieper-Samec, PhD

Serono International, 15bis ch. des Mines, 1211 Geneva, Switzerland

David Schrama, PhD

Department of Dermatology, University of Würzburg
Josef-Schneider Str. 2, 97080 Würzburg, Germany

Wolfram Sterry, Prof.

Department of Dermatology and Allergy, Skin Cancer Center Charité
Charité-Universitätsmedizin Berlin, Fabeckstr. 60 – 62, 14195 Berlin, Germany

Peter C. Taylor, MA, PhD, FRCP

The Kennedy Institute of Rheumatology Division, Faculty of Medicine,
Imperial College London, 1 Aspenlea Road, London, W6 8LH, UK

Timothy N.C. Wells, PhD

Serono International, 15bis ch. des Mines, 1211 Geneva, Switzerland

Maria Wiekowski, PhD

Department of Immunology, Schering-Plough Research Institute
2015 Galloping Hill Road, Kenilworth, NJ 07033, USA